Evidence map›Paper›PMID 32191268›Full record

ArticleJAMA ophthalmology2020

Genomic and Transcriptomic Tumor Heterogeneity in Bilateral Retinoblastoma.

Ursula Winter, Daiana Ganiewich, Daniela Ottaviani, Santiago Zugbi, Rosario Aschero, Juan Martin Sendoya, Eduardo G Cafferata, Marcela Mena, Mariana Sgroi, Claudia Sampor and 11 more

Erratum issuedOpen access · bronzeAbstract readCase ReportsComparative Study
In one paragraph

Article in JAMA ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Error in Author Name.JAMA ophthalmology · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 3 countries.

Ursula WinterPrecision Medicine, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina.
Daiana GaniewichPrecision Medicine, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina.
Daniela OttavianiCentre National de la Recherche Scientifique, Unité Mixte de Recherche 144, Institut Curie, Paris, France.
Santiago ZugbiPrecision Medicine, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina.
Rosario AscheroNational Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina.
Juan Martin SendoyaLaboratory of Molecular and Cellular Therapy, Instituto Leloir, Buenos Aires, Argentina.
Eduardo G CafferataNational Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina.
Marcela MenaPrecision Medicine, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina.
Mariana SgroiOphthalmology Service, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina.
Claudia SamporOncology Service, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina.
Fabiana LubienieckiPathology Service, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina.
Adriana FandiñoOphthalmology Service, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina.
Martin C AbbaNational Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina.
François DozSoins, Innovation, Recherche, en Oncologie de l'Enfant, de l'Adolescent et de l'Adulte Jeune (SIREDO) Oncology Center, Institut Curie, Paris, France.
Osvaldo PodhjacerNational Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina.
Angel Montero CarcabosoPreclinical Therapeutics and Drug Delivery Research Program and Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona, Spain.
Eric LetouzéCentre de Recherche des Cordeliers, Sorbonne Universités, Institut National de la Santé et de la Recherche Médicale, Paris, France.
François RadvanyiCentre National de la Recherche Scientifique, Unité Mixte de Recherche 144, Institut Curie, Paris, France.
Guillermo L ChantadaPrecision Medicine, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina.
Andrea S LleraNational Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina.
Paula SchaiquevichPrecision Medicine, Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina.
Garrahan Hospital · ARCentro Científico Tecnológico - San Juan · ARFundación Instituto Leloir · ARInstitut Curie · FRHospital Sant Joan de Déu Barcelona · ESLa Ligue Contre le Cancer · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Comprehensive understanding of the genomic and gene-expression differences between retinoblastoma tumors from patients with bilateral disease may help to characterize risk and optimize treatment according to individual tumor characteristics. Objective: To compare the genomic features between each eye and a specimen from an orbital relapse in patients with bilateral retinoblastoma. Design, Setting, and Participants: In this case, 2 patients with retinoblastoma underwent upfront bilateral enucleation. Tumor samples were subjected to genomic and gene-expression analysis. Primary cell cultures were established from both of the tumors of 1 patient and were used for gene-expression studies. Main Outcomes and Measures: Whole-exome sequencing was performed on an Illumina platform for fresh tumor samples and DNA arrays (CytoScan or OncoScan) were used for paraffin-embedded samples and cell lines. Gene-expression analysis was performed using Agilent microarrays. Germinal and somatic alterations, copy number alterations, and differential gene expression were assessed. Results: After initial bilateral enucleation, patient 1 showed massive choroidal and laminar optic nerve infiltration, while patient 2 showed choroidal and laminar optic nerve invasion. Patient 1 developed left-eye orbital recurrence and bone marrow metastasis less than 1 year after enucleation. Both ocular tumors showed gains on 1q and 6p but presented other distinct genomic alterations, including an additional gain in 2p harboring the N-myc proto-oncogene (MYCN) in the left tumor and orbital recurrence. Similar copy number alterations between the orbital recurrence and the left eye supported the origin of the relapse, with an additional 11q loss only detected in the orbital relapse. Specimens from patient 2 showed common copy number gains and losses, but further evolution rendered a 2p gain spanning MYCN in the left tumor. For this patient, microarray expression analysis showed differential expression of the MYCN and the forkhead box protein G1 (FOXG1) gene pathways between the left and right tumors. Conclusions and Relevance: Differential genomic and gene expression features were observed between tumors in 2 patients with bilateral disease, confirming intereye heterogeneity that might be considered if targeted therapies are used in such patients. Chromosomal alteration profile supported the origin of the orbital recurrence from the homolateral eye in 1 patient. Loss in chromosome 11q may have been associated with extraocular relapse in this patient.

Indexed as

Genetic HeterogeneityGenomicsTranscriptomeCell Line, TumorDNA Copy Number VariationsDNA, NeoplasmExome SequencingEye EnucleationGene Expression Regulation, NeoplasticHigh-Throughput Nucleotide SequencingHumansLoss of HeterozygosityPolymorphism, Single NucleotideProto-Oncogene MasRetinal NeoplasmsRetinoblastomaDNA, NeoplasmMAS1 protein, humanProto-Oncogene Mas

Identifiers

PMID32191268
PMCPMC7082772
OpenAlexW3011649872

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.